Investor Presentaiton
Torrent - Current standing & Long term strategy
India (1608 Crs)
Among Top 15 cos., Strong presence in
CV/CNS/VMN/GI market
Strategy: Strengthening access in Dermatology,
Gynaecology, Oncology, Nephrology, Pain
Continuous focus on FF Productivity (10 lacs+),
Specialties & Scientific model
Revival of "Turrant" NI Pipeline - 180 products in
the next 5 years
USA (827 Crs)
Late entrant, Duloxetine, Aripiprazole
among Early entry players
Strategy: Strengthening ANDA pipeline,
Entry into Differentiated products, In-
licensing
TPL
Emerging markets (954 Crs)
No. 1 Indian company in Brazil, Philippines
Strategy: Brand building & Specialty focus in
CV/CNS/Gastro.
Continuous focus on FF Productivity
EU, Distributor driven Models (926 Crs)
Among top players in Germany
Strategy: Out-licensing, Entry into
differentiated products, In-licensing
CV- Cardiovascular, CNS - Central Nervous system, VMN - Vitamins Minerals Nutrients, GI-Gastrointestinal, BG -
Branded Generics, FF Field force* 2014-15 Base
SView entire presentation